Innovative Research Award
Kun Bu
University of South Florida, United States
Kun Bu is a researcher affiliated with the University of South Florida whose scholarly contributions focus on cardiovascular pharmacology, adverse drug event analysis, transcriptomic profiling, and computational biomedical research. The researcher has participated in multidisciplinary studies examining cardiovascular safety, pharmacovigilance, and molecular mechanisms associated with therapeutic interventions. Through publications indexed in Scopus and peer-reviewed scientific journals, the researcher has contributed to investigations involving electronic health records, FDA adverse event reporting data, and transcriptomic methodologies relevant to cardiovascular medicine and drug safety evaluation.[1]
Abstract
The research activities of Kun Bu are centered on cardiovascular pharmacology, pharmacovigilance, and bioinformatics-driven approaches for evaluating therapeutic safety and adverse cardiovascular outcomes. The researcher has contributed to studies integrating FDA Adverse Event Reporting System (FAERS) data, electronic health records, and transcriptomic analyses to investigate drug-associated cardiovascular risks and molecular mechanisms. These investigations support evidence-based evaluation of therapeutic safety and contribute to broader understanding of adverse cardiovascular reactions associated with clinical pharmacotherapy.[2]
Keywords
- Cardiovascular Pharmacology
- Pharmacovigilance
- FAERS Analysis
- Transcriptomics
- Drug Safety
- Electronic Health Records
- Cardiovascular Risk Assessment
- Biomedical Data Science
Introduction
Cardiovascular pharmacology is an evolving scientific discipline that combines molecular biology, clinical medicine, and computational analysis to evaluate therapeutic efficacy and drug-related adverse effects. Modern pharmacovigilance research increasingly incorporates large-scale biomedical databases and transcriptomic profiling to identify molecular pathways associated with cardiovascular complications and treatment outcomes.[3] Kun Bu has contributed to this interdisciplinary field through collaborative investigations involving adverse event reporting systems, transcriptomic analysis, and integrated biomedical data interpretation. The researcher’s work addresses clinically relevant questions associated with cardiovascular safety, adverse drug reactions, and translational pharmacological research within cardiovascular medicine.[1]
Research Profile
Kun Bu is affiliated with the University of South Florida and has developed an academic profile focused on cardiovascular pharmacology and computational biomedical research. According to available Scopus metrics, the researcher has accumulated 68 citations with an h-index of 6, reflecting scholarly visibility and research engagement within the scientific literature.[1] The publication portfolio includes peer-reviewed journal articles in journals such as Pharmaceuticals and Genes, with studies addressing cardiovascular risks associated with COVID-19 therapeutics, dexmedetomidine-associated bradycardia, and statin-associated rhabdomyolysis. These contributions emphasize integration of pharmacological data analytics and molecular profiling techniques.[2]
Research Contributions
One of the researcher’s notable contributions involves integrated analysis of cardiovascular risks associated with COVID-19 therapeutics using FAERS data, electronic health records, and transcriptomics. This work explores potential adverse cardiovascular effects linked to therapeutic interventions and contributes to improved pharmacovigilance methodologies.[2] Additional research examined the association between dexmedetomidine and bradycardia through combined analysis of adverse event reporting systems and transcriptomic profiles. The study contributes to understanding molecular mechanisms and clinical patterns associated with cardiovascular adverse reactions.[3] The researcher has also contributed to investigations regarding statin-associated rhabdomyolysis using transcriptomic and FAERS-based methodologies. Such studies support ongoing evaluation of therapeutic safety and risk stratification within cardiovascular pharmacology and clinical medicine.[4]
Publications
- Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics. Pharmaceuticals (2026). DOI: 10.3390/ph19040574
- The Association Between Dexmedetomidine and Bradycardia: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes (2025). DOI: 10.3390/genes16060615
- The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes (2025). DOI: 10.3390/genes16030248
Research Impact
The scholarly contributions of Kun Bu support the advancement of cardiovascular pharmacology and translational biomedical research. By integrating transcriptomics, adverse event databases, and electronic health records, the researcher’s studies contribute to improved understanding of cardiovascular safety profiles and drug-associated adverse reactions.[2] The citation profile and interdisciplinary publication record demonstrate measurable academic engagement within pharmacology and cardiovascular medicine. The research output contributes to contemporary discussions concerning therapeutic safety assessment and computational approaches in biomedical science.[1]
Award Suitability
Kun Bu’s research profile demonstrates relevance to the International Research Awards on Cardiology & Cardiovascular Medicine through contributions to cardiovascular pharmacology and pharmacovigilance research. The researcher’s investigations address clinically important issues involving drug safety, adverse cardiovascular outcomes, and molecular risk assessment.[3] The combination of peer-reviewed publications, citation metrics, and interdisciplinary scientific methodologies supports recognition within the field of cardiovascular medicine. The researcher’s contributions align with ongoing efforts to improve evidence-based therapeutic evaluation and cardiovascular risk analysis.[4]
Conclusion
Kun Bu has contributed to the interdisciplinary field of cardiovascular pharmacology through research focused on adverse drug event analysis, transcriptomic profiling, and integrated biomedical data interpretation. The researcher’s publication record demonstrates engagement in clinically relevant investigations involving cardiovascular risk assessment and pharmacovigilance. These scholarly contributions support ongoing advancement in cardiovascular medicine and evidence-based therapeutic safety evaluation.[2]
External Links
References
- Elsevier. (n.d.). Scopus author details: Kun Bu, Author ID 57223366298. Scopus. https://www.scopus.com/authid/detail.uri?authorId=57223366298
- Zhu, X., Kuppa, S. A., Umeukeje, G., Morris, R., Bui, L., Bu, K., Zhang, J., Wei, J., & Cheng, F. (2026). Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics. Pharmaceuticals. DOI: https://doi.org/10.3390/ph19040574
- Morris, R., Kuppa, S. A., Zhu, X., Bu, K., Han, W., & Cheng, F. (2025). The Association Between Dexmedetomidine and Bradycardia: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes. DOI: https://doi.org/10.3390/genes16060615
- Morris, R., Bu, K., Han, W., Wood, S., Hernandez Velez, P. M., Ward, J., Crescitelli, A., Martin, M., & Cheng, F. (2025). The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes.
DOI: https://doi.org/10.3390/genes16030248